Posted: Thu 4th Nov 2021

First anti-viral pill for Covid-19 that can be taken at home approved for use in the UK.

News and Info from Deeside, Flintshire, North Wales
This article is old - Published: Thursday, Nov 4th, 2021

The UK has become the first country to approve an anti-viral pill that can be taken at home to treat COVID-19.

Health and Social Care Secretary Sajid Javid (UK Government) said the oral treatment will be a “gamechanger for the most vulnerable and the immunosuppressed.”

The UK’s Medicines and Healthcare products Regulatory Agency has said the antiviral Lagevrio (molnupiravir) pill is safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease.

This follows a rigorous review of its safety, quality and effectiveness by the UK regulator and the government’s independent expert scientific advisory body, the Commission on Human Medicines, making it the first oral antiviral for the treatment of COVID-19 to be approved.

Developed by Ridgeback Biotherapeutics and Merck Sharp & Dohme (MSD), Lagevrio works by interfering with the virus’ replication. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.

Based on the clinical trial data, Lagevrio is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible following a positive COVID-19 test and within five days of symptoms onset

Molnupiravir has been authorised for use in people who have mild to moderate COVID-19 and at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.

Health and Social Care Secretary Sajid Javid said: “Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for COVID-19.”

“This will be a gamechanger for the most vulnerable and the immunosuppressed, who will soon be able to receive the ground-breaking treatment.”

“The UK is leading the way to research, develop and roll out the most exciting, cutting-edge treatments, and my thanks goes to the expert teams at the MHRA and MSD for this triumph, as well as the Antivirals Taskforce who have procured the treatment.

“We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible

“This antiviral will be an excellent addition to our armoury against COVID-19, and it remains vital everyone comes forward for their life-saving COVID-19 vaccine – particularly those eligible for a booster – to ensure as many people as possible are protected over the coming months.”

Dr June Raine, MHRA Chief Executive, said: “Following a rigorous review of the data by our expert scientists and clinicians, we are satisfied that Lagevrio (molnupiravir) is safe and effective for those at risk of developing severe COVID-19 disease and have granted its approval.

“Lagevrio is another therapeutic to add to our armoury against COVID-19. It is also the world’s first approved antiviral for this disease that can be taken by mouth rather than administered intravenously. This is important, because it means it can be administered outside of a hospital setting, before COVID-19 has progressed to a severe stage.

“With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data.”

Professor Sir Munir Pirmohamed, Chair of the Commission on Human Medicines, said: “The Commission on Human Medicines and its COVID-19 Therapeutics Expert Working Group has independently reviewed the data and endorses the MHRA’s regulatory approval of Lagevrio.

“In clinical trials, Lagevrio was found to be effective in reducing the risk of hospitalisation or death for at-risk non-hospitalised adults with mild to moderate COVID-19 by 50%.

“Based on this and other data that has been carefully reviewed by the Commission and its expert group, it is clear Lagevrio is another safe and effective treatment to help us in our fight against COVID-19.”

Lagevrio is not intended to be used as a substitute for vaccination against COVID-19.

The government and the NHS will confirm how this COVID-19 treatment will be deployed to patients in due course.

[Photo: merck.com]

Spotted something? Got a story? Send a Facebook Message | A direct message on Twitter | Email: News@Deeside.com

Public Notice Advert

CQLCP

Latest News

  • North Wales Police: Greenfield residents called to action in drug fight
  • Wales’ diminished role in UK-EU relations post-Brexit: MSs warn of lack of democratic debate
  • Only 10 days left to claim pension credit for pensioners in Wales and secure £299 Cost of Living boost

  • More...

    North Wales Police: Greenfield residents called to action in drug fight

    News

    Wales’ diminished role in UK-EU relations post-Brexit: MSs warn of lack of democratic debate

    News

    Only 10 days left to claim pension credit for pensioners in Wales and secure £299 Cost of Living boost

    News

    Welsh Government helping to make children veg chomp-ions

    News

    Senedd: Betsi ‘nowhere close to seeing the improvements that we should be seeing after a year in special measures’

    News

    Greek mythology drama comes to Theatr Clwyd in Beautiful Evil Things

    News

    CCTV appeal after Saltney tyre slashings

    News

    Welsh Government faces criticism for failing to deliver real living wage promise

    News

    University of Chester experts fill in blank space in discussion on Taylor Swift’s accent shifts

    News